NasdaqGS:ABCLLife Sciences
AbCellera Biologics (ABCL) Is Down 5.9% After Vertex-Backed T-Cell Engager Collaboration Announcement
AbCellera Biologics Inc. recently announced a collaboration with Vertex Pharmaceuticals to research, develop, manufacture, and commercialize multispecific T-cell engagers for autoimmune diseases and other conditions, with AbCellera receiving US$28 million in upfront payments plus eligibility for milestones and tiered royalties.
This agreement broadens the use of AbCellera’s T-cell engager platform while allowing Vertex to fund all R&D, potentially adding a new stream of partnered, downstream...